Mission: Cure and AvoMD Partner to Improve Exocrine Pancreatic Insufficiency Diagnosis and Treatment

October 03, 2023 08:52 AM AEDT | By EIN Presswire
 Mission: Cure and AvoMD Partner to Improve Exocrine Pancreatic Insufficiency Diagnosis and Treatment
Image source: EIN Presswire
NEW YORK, NEW YORK, U.S.A., October 2, 2023 /EINPresswire.com/ -- Mission: Cure in partnership with AvoMD, a software company that translates clinical evidence into the workflow, has developed a tool for the point-of-care to improve treatment for patients with exocrine pancreatic insufficiency (EPI).

The interactive EPI tool is available for free in all electronic health records (EHRs) on the AvoMD application, which can also be accessed on the web. The Mission: Cure and AvoMD joint initiative aims to support primary care physicians, nurse practitioners, physician assistants, medical students, residents, and trainees in treating patients with EPI.

Exocrine pancreatic insufficiency is reported in 60%–90% of chronic pancreatitis (CP) patients within 10–12 years from diagnosis and in people with cystic fibrosis, celiac, and other conditions. Despite its high prevalence, limited specialty care and education have led to frequent misdiagnosis or underdiagnosis, and its symptoms are often mistaken for other digestive disorders. This new initiative by Mission: Cure and AvoMD seeks to address this problem, says Megan Golden, CEO and Co-Founder of Mission: Cure.

"We understand the struggles people face in receiving adequate care for EPI and believe this situation is unacceptable," says Golden. "The lack of specialized training for clinicians on this condition has contributed to its underdiagnosis and undertreatment. We are confident that this tool will make a significant impact on patient outcomes. Our joint initiative with AvoMD is a crucial step towards ensuring that patients with EPI receive the care and attention they deserve."

For clinicians, this platform will make diagnosing and treating EPI much less complex.

“The tool is truly amazing,” says Mary Phillips, guideline author and Advanced Clinical Practitioner at Royal Surrey County Hospital. “It will help assist in the accurate diagnosis of EPI, even in the absence of any pancreatic pathology.”

Those who would like to implement AvoMD’s point-of-care tool can do so by contacting AvoMD directly. For feedback on the tool, Mission: Cure can be contacted directly through its website.

###

Mission: Cure is a coalition of doctors, researchers, patients, and entrepreneurs pioneering a new approach to curing diseases through innovative, outcome-based financing. Headquartered out of New York, New York, and operating virtually, Mission: Cure collaborates with impact investors and payers to discover life-altering therapies and bring them to patients. Currently, Mission: Cure is focused on accelerating a cure for pancreatitis. Support Mission: Cure by donating at mission-cure.org, liking Mission: Cure on Facebook, following Mission: Cure on Instagram, Twitter, and LinkedIn, and subscribing to its YouTube Channel.

AvoMD is an EHR-integrated pathway and decision support solution. Content comes from leading societies or can be customized from institutional pathways via AvoMD’s drag-and-drop builder (rule-based or AI). Clinicians use AvoMD for diagnostic and treatment algorithms, lab interpretation, and ensuring insurance coverage for medications. The software can automatically pull in labs, pend relevant orders, and reduce documentation burden via automatic note generation. AvoMD saves clinicians over 50 percent of their time in clinical decision-making at the bedside while improving outcomes and reducing costs.

Use the free version of AvoMD on the web.
Learn more at avomd.io, or email [email protected].

Skye Shrader
Mission: Cure
[email protected]
+1 401-375-2873
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
YouTube


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.